BSc Eng - BiondVax Pharmaceuticals Chief Officer
| BVXVDelisted Stock | USD 1.35 0.03 2.17% |
Insider
BSc Eng is Chief Officer of BiondVax Pharmaceuticals
| Age | 40 |
| Phone | 972 8 930 2529 |
| Web | https://www.biondvax.com |
BiondVax Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.3089) % which means that it has lost $0.3089 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (56.0153) %, meaning that it created substantial loss on money invested by shareholders. BiondVax Pharmaceuticals' management efficiency ratios could be used to measure how well BiondVax Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.BiondVax Pharmaceuticals currently holds 21.54 M in liabilities. BiondVax Pharmaceuticals has a current ratio of 1.68, which is within standard range for the sector. Note, when we think about BiondVax Pharmaceuticals' use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Eddie Sullivan | SAB Biotherapeutics | 58 | |
| Yassine Bendiabdallah | Pasithea Therapeutics Corp | 40 | |
| Daniela Santiesteban | Salarius Pharmaceuticals | N/A | |
| Joan JD | Pharvaris BV | 60 | |
| WenChen MD | Surrozen | 60 | |
| RA MSc | Pharvaris BV | 43 | |
| Sonia DPHIL | PepGen | 38 | |
| Jennifer Cormier | PepGen | N/A | |
| Roy MD | Oramed Pharmaceuticals | N/A | |
| MBA CFA | Vaccinex | 50 | |
| Mark Newman | GeoVax Labs | 69 | |
| David Jin | Avenue Therapeutics | 34 | |
| , MBA | Molecular Partners AG | 51 | |
| Charles Williams | Surrozen | 44 | |
| Paul MD | AN2 Therapeutics | 54 | |
| CPA CPA | BioLineRx | 48 | |
| Ofer BSc | Mediwound | 51 | |
| Jeffrey Welch | GeoVax Labs | N/A | |
| MS JD | Surrozen | 62 | |
| Lawrence CPA | Adial Pharmaceuticals | 68 | |
| Wim Souverijns | Pharvaris BV | 53 | |
Management Performance
| Return On Equity | -56.02 | |||
| Return On Asset | -0.31 |
BiondVax Pharmaceuticals Leadership Team
Elected by the shareholders, the BiondVax Pharmaceuticals' board of directors comprises two types of representatives: BiondVax Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of BiondVax. The board's role is to monitor BiondVax Pharmaceuticals' management team and ensure that shareholders' interests are well served. BiondVax Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, BiondVax Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| CPA CPA, Chief Officer | ||
| BSc Eng, Chief Officer | ||
| Tamar BenYedidia, Chief Scientific Officer | ||
| Dalit Fischer, Head RD | ||
| MSc MBA, CEO Director | ||
| Moran LLB, Chief Staff |
BiondVax Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is BiondVax Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -56.02 | |||
| Return On Asset | -0.31 | |||
| Current Valuation | 21.94 M | |||
| Shares Outstanding | 3.65 M | |||
| Shares Owned By Insiders | 20.01 % | |||
| Shares Owned By Institutions | 10.69 % | |||
| Number Of Shares Shorted | 4.88 K | |||
| Price To Earning | (4.91) X | |||
| Price To Book | 7.48 X | |||
| EBITDA | (10.5 M) |
Thematic Opportunities
Explore Investment Opportunities
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest. You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
Other Consideration for investing in BiondVax Stock
If you are still planning to invest in BiondVax Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the BiondVax Pharmaceuticals' history and understand the potential risks before investing.
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account |